{'fraction_non_alphanumeric': 0.017605633802816902, 'fraction_numerical': 0.0035211267605633804, 'mean_word_length': 6.294871794871795, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group

The ultimate goal of chronic myeloid leukemia management in the tyrosine kinase inhibitor (TKI) era for patients who obtain deep molecular responses is maintaining a durable off‐treatment response after treatment discontinuation; this situation is called treatment‐free remission (TFR). Knowledge accumulated during the last 10 years justifies moving TFR strategies from research to clinical practice.